
Mangoceuticals Partners with T7X to Become the First Nasdaq-Listed Company to Offer Tokenized Preferred Stock on the T7X Platform
Mangoceuticals, a Nasdaq-listed telemedicine company, has announced a partnership with T7X to issue Series D Cumulative Convertible Preferred Stock natively on the Trusted Smart Chain. The company filed a Form 1-A offering statement with the SEC to raise up to $10 million by selling 1,000,000 shares at $10.00 each. This initiative marks a significant milestone as Mangoceuticals expects to become the first Nasdaq-listed firm to utilize the T7X platform for tokenized security issuance. The preferred stock features an 8% annual dividend and includes programmable compliance controls, such as KYC and AML, embedded directly into the blockchain protocol. By issuing these securities on-chain, the company aims to enhance settlement efficiency and transparency while limiting near-term dilution for common shareholders. The offering is structured under Regulation A, Tier 2, and requires final SEC qualification before proceeding. This development highlights the growing trend of public companies adopting native on-chain infrastructure to modernize capital formation and investor relations.
